期刊文献+

抗肿瘤药的常见不良反应及防治 被引量:33

Prevention and Management of Common ADRs Induced by Antitumor Drugs
下载PDF
导出
摘要 目的:对抗肿瘤药所致的不良反应及其防治进行归纳总结,以期为临床合理用药提供参考。方法:查阅国内外相关文献,从消化系统不良反应、造血系统不良反应、泌尿系统不良反应、肝毒性反应、心脏毒性反应、肺毒性反应、神经系统毒性反应、过敏反应等方面进行总结分析。结果及结论:抗肿瘤药物的不良反应较多,程度类型各不相同,应引起重视,早期预防、密切监测、及时处理,以提高药物疗效,减轻患者的痛苦。 OBJECTIVE: To summarize the prevention and management of ADRs induced by antitumor drugs to provide references for their rational administration in the clinic. METHODS: A summarization and analysis were carried out regarding the toxic reactions of digestive system, hematopoietic system, urinary system, liver, heart, lung, nervous system and allergic reactions etc by reviewing the related literatures. RESULTS & CONCLUSION: Antitumor drugs can lead to muhisystem ADRs of different degree and different types, therefore, great importance should be attached to its early prevention, close monitoring and timely management to enhance efficacy of drugs and relieve pains of patients.
出处 《中国医院用药评价与分析》 2007年第1期76-79,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 抗肿瘤药 不良反应 合理用药 antitumor drugs ADRs rational use of drugs
  • 相关文献

参考文献11

二级参考文献79

  • 1江泽飞,宋三泰,徐建明,刘晓晴,李彦博,赵平瑜.单用去甲长春花碱治疗复发转移乳癌[J].中华肿瘤杂志,1996,18(3):208-210. 被引量:45
  • 2彭吉军.与干扰素有关的突发性耳聋[J].国外医学:内科学分册,1995,22(7):318-318.
  • 3[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
  • 4[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
  • 5[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
  • 6[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
  • 7[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
  • 8[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144
  • 9[7]Kupsch P,Henning BF,Passarge K,et al.Results of a phaseⅠ trial of sorafenib (BAY 43 -9006) in combination with oxaliplatin in patients with refractory solid tumors,including colorectal cancer.Clin Colorectal Cancer,2005,5 (3):188
  • 10[8]Clark JW,Eder JP,Ryan D,et al.Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor,BAY 43 -9006,in patients with advanced,refractory solid tumors.Clin Cancer Res,2005,1; 11 (15):5472

共引文献130

同被引文献290

引证文献33

二级引证文献207

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部